<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventy-seven cytomegalovirus (CMV)-seronegative marrow transplant patients were randomized in a prospective controlled trial comparing the use of leukocyte-depleted platelets plus CMV-seronegative red blood cells with standard unscreened blood products for the prevention of primary <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> during the first 100 days after transplant </plain></SENT>
<SENT sid="1" pm="."><plain>Eligible patients included CMV-seronegative patients undergoing autologous transplant or seronegative patients undergoing allogeneic transplant for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:e sem="disease" ids="C0935681" disease_type="Neoplastic Process" abbrv="">non-hematologic malignancy</z:e> who had seronegative marrow donors </plain></SENT>
<SENT sid="2" pm="."><plain>Patients and marrow donors were serologically screened for CMV and randomized before conditioning for transplant and followed for <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> with weekly cultures of throat, urine, and blood and with weekly CMV serologies until day 100 after transplant </plain></SENT>
<SENT sid="3" pm="."><plain>Leukocyte-depleted platelets were prepared by centrifugation, a procedure that removed greater than 99% of leukocytes </plain></SENT>
<SENT sid="4" pm="."><plain>There were no <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infections</z:e> observed in 35 evaluable treatment patients compared with seven <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in 30 evaluable control patients (P = .0013) </plain></SENT>
<SENT sid="5" pm="."><plain>There was no statistically significant difference in the mean number of platelet concentrates in the treatment patients (164 concentrates) compared with the control patients (126 concentrates) </plain></SENT>
<SENT sid="6" pm="."><plain>Leukocyte-depleted platelets plus CMV-seronegative red blood cells are highly effective in preventing primary <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> after marrow transplant </plain></SENT>
</text></document>